Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

417 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of Treatment-Related Toxicity With Hypofractionated or Conventionally Fractionated Radiation Therapy for Prostate Cancer: A National Population-Based Study.
Sujenthiran A, Parry M, Nossiter J, Berry B, Cathcart PJ, Clarke NW, Payne H, van der Meulen J, Aggarwal A. Sujenthiran A, et al. Among authors: payne h. Clin Oncol (R Coll Radiol). 2020 Aug;32(8):501-508. doi: 10.1016/j.clon.2020.02.004. Epub 2020 Mar 3. Clin Oncol (R Coll Radiol). 2020. PMID: 32143901
RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery).
Parker C, Clarke N, Logue J, Payne H, Catton C, Kynaston H, Murphy C, Morgan R, Morash C, Parulekar W, Parmar M, Savage C, Stansfeld J, Sydes M; RADICALS Trial Management Group. Parker C, et al. Among authors: payne h. Clin Oncol (R Coll Radiol). 2007 Apr;19(3):167-71. doi: 10.1016/j.clon.2007.01.001. Epub 2007 Feb 7. Clin Oncol (R Coll Radiol). 2007. PMID: 17359901 Clinical Trial. No abstract available.
Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy.
Parker C, Sydes MR, Catton C, Kynaston H, Logue J, Murphy C, Morgan RC, Mellon K, Morash C, Parulekar W, Parmar MK, Payne H, Savage C, Stansfeld J, Clarke NW; (RADICALS Trial Management Group). Parker C, et al. Among authors: payne h. BJU Int. 2007 Jun;99(6):1376-9. doi: 10.1111/j.1464-410X.2007.06844.x. Epub 2007 Apr 8. BJU Int. 2007. PMID: 17428247 Clinical Trial. No abstract available.
The first national clinical audit of prostate cancer care.
Cathcart P, Nossiter J, Aggarwal A, Rashbass J, Lyratzopoulos Y, Payne H, Neal DE, van der Meulen J; National Prostate Cancer Audit group. Cathcart P, et al. Among authors: payne h. BJU Int. 2013 Nov;112(7):883-4. doi: 10.1111/bju.12365. BJU Int. 2013. PMID: 24053511 No abstract available.
The National Prostate Cancer Audit - introducing a new generation of cancer audit.
Aggarwal A, Cathcart P, Payne H, Neal D, Rashbass J, Nossiter J, van der Meulen J. Aggarwal A, et al. Among authors: payne h. Clin Oncol (R Coll Radiol). 2014 Feb;26(2):90-3. doi: 10.1016/j.clon.2013.10.006. Epub 2013 Nov 5. Clin Oncol (R Coll Radiol). 2014. PMID: 24211033 No abstract available.
Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology.
Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou E, Emberton M, Fitzpatrick JM, Heidenreich A, Hughes S, Joniau S, Kattan M, Mottet N, Oudard S, Payne H, Saad F, Sugihara T. Droz JP, et al. Among authors: payne h. Lancet Oncol. 2014 Aug;15(9):e404-14. doi: 10.1016/S1470-2045(14)70018-X. Lancet Oncol. 2014. PMID: 25079103 Review.
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators. James ND, et al. Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21. Lancet. 2016. PMID: 26719232 Free PMC article. Clinical Trial.
Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer.
Davda R, Hughes S, Jones R, Crabb SJ, Troup J, Payne H. Davda R, et al. Among authors: payne h. Clin Oncol (R Coll Radiol). 2016 Jun;28(6):376-85. doi: 10.1016/j.clon.2016.01.006. Epub 2016 Feb 11. Clin Oncol (R Coll Radiol). 2016. PMID: 26874654 Free article. Afrikaans, English.
417 results